以下是内容的中文翻译： 斯坦·德鲁肯米勒（Stan Druckenmiller），这位传奇的宏观投资者，以其在1981年至2010年期间在杜肯资本（Duquesne Capital）实现30%的年化收益率和无亏损年份而闻名。在与摩根士丹利（Morgan Stanley）的伊利亚娜·布扎利（Ilyana Buzali）的对话中，他分享了自己独特的投资理念和“宝贵教训”。德鲁肯米勒现在管理着他的家族办公室，并通过慈善事业倡导教育和医学研究。 他首先通过近期对梯瓦制药（Teva Pharmaceutical）的交易来阐释自己的投资过程。2023年年中，当AI股票过热时，他的团队发现了梯瓦——一家市盈率仅为6倍的“无趣的仿制药公司”。在新任CEO理查德·弗朗西斯（Richard Francis）的领导下，梯瓦正在从仿制药转向高增长的生物类似药。市场，由价值投资者（因其向增长型策略转型而选择卖出）和成长型投资者（尚未买入）组成，有效地忽视了这一转型。德鲁肯米勒将此视为一个机会，他表示：“如果你只看当下，你赚不到钱。如果你尝试展望未来……”随着弗朗西斯证明了他的策略，梯瓦的股价从16美元翻倍至32美元。 德鲁肯米勒承认他并非每个领域的专家，尤其是生物技术。他严重依赖团队的判断和他“对市场将如何接纳这种变化的‘感觉’”。他坦率地说，他的优势不在于智商，而在于“果断决策”。他称自己为“白痴学者”（idiot savant），拥有一种狭隘的智力形式，强调不仅要筛选数据，还要筛选他信任的专家的热情。 回顾他的职业生涯，德鲁肯米勒将自己的成功部分归因于一种“天生具有复利赚钱的天赋”，但也归功于关键的指导。他的第一位导师教会了他基本原理，而与他共事的乔治·索罗斯（George Soros）则传授了关于“头寸管理”的宝贵经验。索罗斯教导他：“重要的不是你对或错。重要的是你对了时赚了多少，错了时亏了多少。” 关于当前市场，德鲁肯米勒认为美国经济强劲并将变得更强，美联储可能降息。然而，他指出估值偏高。他对“即将到来的巨大颠覆和巨大变革”感到兴奋，这预示着宏观投资的复苏。他目前的投资组合较少受AI驱动，包括在日本和韩国的头寸。他看跌美元，理由是海外对美元的过度敞口和贸易失衡。他做多铜，这是一个“巨大的共识交易”，原因在于供应有限以及AI/数据中心的需求，并持有一些黄金作为地缘政治对冲。为了平衡这些风险资产，他做空债券，预计它们将盈亏平衡，或在增长导致通胀时提供保护。 尽管他通常会为18个月到三年构思交易，但他很务实，承认曾在一个“三年期交易”中在五天内逆转。他认为“逆向投资被高估了”，指出索罗斯认为人群有80%的时间是对的。他重视极度信念，尤其是在独自一人时，但如果论点和趋势强劲，他也不回避拥挤的交易。 他关于英伟达（Nvidia）的交易就体现了这一点。2022年初，他的年轻团队以及他观察到斯坦福大学学生从加密货币转向AI，促使他买入了少量头寸。两周后ChatGPT的发布，以及随后摩根士丹利分析师的一份宏观报告证实，让他确信AI的巨大潜力，促使他将头寸翻倍，然后翻三倍。尽管他坚信该股会“至少两三年”飙升，但他却以800美元的价格卖出（该股此前已从150美元上涨），后来当它涨到1400美元时感到后悔。他承认违反了自己的长期观点，将其归因于对如此快速的收益感到不安。 德鲁肯米勒已经“摈弃”了技术分析和价格与新闻动态关系的高效性。他声称，这两者都“被过度使用了”。技术分析，曾经独特，现在“只有20%的效率”，因为每个人都在使用它。同样，坏消息发布后股票上涨这种曾经可靠的模式也消失了，因为“其他所有人都学会了这一点”。 他反思自己现在拥有更多的智慧和工具，但比年轻时更缺乏“勇气”，承认自己“临阵退缩”。他是一个“输不起的人”，被一种“渴望胜利的病态心理”驱动。他最惨痛的教训包括他“数百个错误”，比如完美卖出了1999年纳斯达克（NASDAQ）暴涨行情后，又在顶部买入。他花了15年时间与“冒名顶替综合症”（imposter syndrome）作斗争，并学会接受错误和情绪是过程的一部分。他最终的教训是：“接受现实，然后继续前进。”

Stan Druckenmiller, the legendary macro investor known for his 30% annualized returns and no losing years at Duquesne Capital from 1981 to 2010, shared his unique investment philosophy and "hard lessons" in a conversation with Morgan Stanley's Ilyana Buzali. Now managing his family office, Druckenmiller champions education and medical research through philanthropy. He began by illustrating his process with a recent trade in Teva Pharmaceutical. In mid-2023, while AI stocks were overheating, his team identified Teva – a "boring generic drug company" trading at six times earnings. Under new CEO Richard Francis, Teva was transitioning from generics to higher-growth biosimilars. The market, comprised of value investors (selling due to growth strategy) and growth investors (not yet buying), effectively ignored this transformation. Druckenmiller saw this as an opportunity, stating, "If you look at today, you're not going to make any money. If you try and look ahead..." Teva's stock doubled from $16 to $32 as Francis proved his strategy. Druckenmiller admits he isn't an expert in every field, particularly biotech. He relies heavily on his team's judgment and his "feel for how the market will embrace the change." He candidly states his advantage isn't IQ, but "trigger pulling." He refers to himself as an "idiot savant" with a narrow form of intelligence, emphasizing the importance of filtering not just data, but also the enthusiasm of his trusted experts. Reflecting on his career, Druckenmiller attributes his success partly to an "innate gift for compounding money" but also to crucial mentorship. His first mentor taught him the fundamentals, while George Soros, with whom he worked, imparted the invaluable lesson of "sizing." Soros taught him, "It's not whether you're right or wrong. It's how much you make when you're right and how much you lose when you're wrong." Regarding the current market, Druckenmiller believes the U.S. economy is strong and will get stronger, with the Fed likely to cut rates. However, he notes valuations are high. He's excited by the "massive disruption and massive change ahead," signaling a resurgence for macro investing. His current portfolio is less AI-driven, including positions in Japan and Korea. He's bearish on the U.S. dollar, citing foreign overexposure and trade imbalances. He's long copper, a "big consensus trade" due to limited supply and demand from AI/data centers, and holds some gold as a geopolitical hedge. To balance these risk assets, he's short bonds, expecting them to break even or offer protection if growth leads to inflation. While he typically conceptualizes trades for 18 months to three years, he's pragmatic, admitting to reversing a "three-year trade" in five days. He finds "contrarianism overrated," noting Soros believed the crowd is right 80% of the time. He values extreme conviction, especially when alone, but doesn't shy away from crowded trades if the thesis and trend are strong. His Nvidia trade exemplifies this. In early 2022, his young team and observation of Stanford students shifting from crypto to AI, led him to buy a small position. Chat GPT's release two weeks later, followed by a confirming macro call from a Morgan Stanley analyst, convinced him of AI's enormity, leading him to double, then triple his position. Despite his conviction that the stock would soar for "at least two or three years," he sold at $800 (from $150) and later regretted it when it hit $1,400. He confessed to violating his own long-term view, attributing it to discomfort with such rapid gains. Druckenmiller has "unlearned" the high efficacy of technical analysis and the price-versus-news dynamic. Both, he claims, are "loved to death." Technical analysis, once unique, is now "20% as effective" because everyone uses it. Similarly, the once-reliable pattern of stocks rallying after bad news is gone because "everybody else has learned that." He reflects on having more wisdom and tools now but less "courage" than in his younger days, admitting to "chickening out." He's a "sore loser" driven by a "sickness" to win. His hardest lessons involve his "hundreds of mistakes," like buying the top after perfectly selling the 1999 NASDAQ melt-up. He spent 15 years battling "imposter syndrome" and learning to accept that mistakes and emotions are part of the process. His ultimate lesson: "Just get over it and move on."